These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3326612)

  • 1. Controlled-release therapeutic systems: technology applicable to the treatment of oral disease.
    Mirth DB
    Adv Dent Res; 1987 Oct; 1(1):109-18. PubMed ID: 3326612
    [No Abstract]   [Full Text] [Related]  

  • 2. [1st communication on the treatment of burning of the oral mucosa with a synthetic orally applicable depot estrogen].
    Wagner S; Wagner IV
    Dtsch Stomatol; 1970 Nov; 20(11):827-32. PubMed ID: 5274507
    [No Abstract]   [Full Text] [Related]  

  • 3. New long-lasting lozenge protectant vehicle for oral mucosal disease.
    Kutscher AH; Zegarelli EV; Ruiz L; Rosell A; Mehrhof A
    N Y State J Med; 1969 Mar; 69(5):687-9. PubMed ID: 5252482
    [No Abstract]   [Full Text] [Related]  

  • 4. [Development and evaluation of an active substance controlled-release device for use in the oral cavity].
    Diarra M; Pourroy G; Muster D; Zingraff M; Boymond C
    Rev Stomatol Chir Maxillofac; 1998 Jul; 99 Suppl 1():94-8. PubMed ID: 9697239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissolution duration times of a modified long-lasting lozenge formulation in patients with oral lesions.
    Kutscher AH; Zegarelli EV; Metzger J; Ruiz L; Burns A; Ellegood C
    J Oral Med; 1969 Apr; 24(2):51-2. PubMed ID: 5257797
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-lasting lozenges CU 701-1: dissolution duration times in patients with oral mucosal lesions.
    Kutscher AH; Zegarelli EV; Ruiz LM; McAdams W; Baker N; Robinson G
    Ann Dent; 1968 Dec; 27(4):149-50. PubMed ID: 4886473
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-lasting lozenges with triamcinolone acetonide. Treatment of erosive lichen planus of oral mucosa.
    Zegarelli EV; Kutscher AH; Mehrhof A
    N Y State J Med; 1969 Sep; 69(18):2463-4. PubMed ID: 5257612
    [No Abstract]   [Full Text] [Related]  

  • 8. [Has the pharmaceutical industry forgotten about the oral cavity?].
    Muster D; Ben Slama L
    Rev Stomatol Chir Maxillofac; 2006 Apr; 107(2):72-4. PubMed ID: 16738510
    [No Abstract]   [Full Text] [Related]  

  • 9. Local drug delivery for oral mucosal diseases: challenges and opportunities.
    Sankar V; Hearnden V; Hull K; Juras DV; Greenberg MS; Kerr AR; Lockhart PB; Patton LL; Porter S; Thornhill M
    Oral Dis; 2011 Apr; 17 Suppl 1():73-84. PubMed ID: 21382140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-lasting lozenges: dissolution studies with CU 701-1 in patients with oral lesions and in volunteer (normal) subjects.
    Kutscher AH; Kanig JL; Zegarelli EV; Ruiz L
    Mil Med; 1968 Jun; 133(6):471-3. PubMed ID: 4988426
    [No Abstract]   [Full Text] [Related]  

  • 11. Studies in the design and analysis of dental experiments. 13. Balanced incomplete block design.
    Varma AA; Chilton NW; Kutscher AH
    J Dent Res; 1970; 49(5):1166-71. PubMed ID: 5272100
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-lasting lozenge: dissolution duration time in the clinic in patients with oral mucosal lesions.
    Kutscher AH; Zegarelli EV; Ruiz LM; Miller B; Bonfield C
    J Conn State Dent Assoc; 1969 Apr; 43(2):113. PubMed ID: 4976518
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-lasting lozenges CU 701-1: dissolution duration time at home in patients with oral mucosal lesions.
    Kutscher AH; Zegarelli EV; Ruiz L; Miya C; Forester J
    Q Natl Dent Assoc; 1969 Apr; 27(3):76-7. PubMed ID: 5254949
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of acute and chronic pain in the maxillo-facial area by means of a long-acting analgesic].
    Neupel HG
    ZWR; 1970 Jun; 79(11):482-4. PubMed ID: 5267848
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapeutic use of medicinal plant preparations in the treatment of diseases of the oral mucosa].
    Stawiński K
    Czas Stomatol; 1979 Jul; 32(7):687-97. PubMed ID: 294335
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical evaluation of sustained release preparations of cefaclor in dental infections. Comparative double blind clinical studies of sustained release preparations with a regular preparation of cefaclor].
    Horii M; Shimada S; Yamanaka H; Nishimura T; Noshi Y; Okada T; Sasaki T; Inaba O; Takada S; Kimura J
    Jpn J Antibiot; 1985 Apr; 38(4):1117-40. PubMed ID: 3897614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Crohn's disease: a favorable clinical response with delayed-release triamcinolone acetonide intralesional injections.
    Mignogna MD; Fortuna G; Leuci S; Amato M
    Am J Gastroenterol; 2008 Nov; 103(11):2954-5. PubMed ID: 19032484
    [No Abstract]   [Full Text] [Related]  

  • 18. [Principles of geriatric pharmacology. 1. Pharmacokinetics and pharmacodynamics].
    Rossi E; Anzivino F; Dalla S
    Dent Cadmos; 1988 Sep; 56(14):122-3, 125-6. PubMed ID: 3255626
    [No Abstract]   [Full Text] [Related]  

  • 19. Preparation and evaluation of oral controlled-release cilostazol formulation: pharmacokinetics and antithrombotic efficacy in dogs and healthy male Korean participants.
    Shin KH; Yoon G; Yoon IS; Park JW
    J Pharm Pharmacol; 2014 Jul; 66(7):961-74. PubMed ID: 24697278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative studies of the biocompatibility of the oral mucous membrane to therapeutic drugs].
    Geurtsen W; Lost C
    ZWR; 1983 Nov; 92(11):56, 59-61. PubMed ID: 6583900
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.